Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations

Details 詳細情報について

• CRID

  1360855570341502464

• DOI

  10.1093/jjco/hyr079

• ISSN

  14653621

  03682811

• Web Site

  http://academic.oup.com/jjco/article-pdf/41/8/959/5122145/hyr079.pdf

• Data Source

  • Crossref